Diabetic Foot Ulcer (DFU) Treatment Market Analysis Report By Treatment (Biologics, Wound Care Dressings, Therapy Devices), By Ulcer Type (Ischemic, Neuro-Ischemic, Neuropathic), And Segment Forecasts, 2019 - 2025

Industry Insights

The global diabetic foot ulcer treatment market size was valued at USD 3.6 billion in 2017. It is anticipated to expand at a CAGR of 8.2% over the forecast period. Rising prevalence of diabetes and rapidly growing geriatric population worldwide are among the primary growth stimulants for DFU treatment market. Diabetic foot ulcer is one of the major complications of diabetes mellitus, which forms a major characteristic of diabetic foot.

Healing of wounds is typically an innate mechanism. However, certain metabolic disorders such as diabetes mellitus delays typical pace of wound healing process. Diabetic foot ulcers are most commonly caused by irritated or wounded feet, nerve damage, poor circulation, and high blood sugar (hyperglycemia).Unusual swelling, redness, irritation, and stenches on one or both feet are common initial symptoms of foot ulcer.

DFU treatments, usually include control of blood sugar, removal of dead tissue, wound dressings, and negative pressure therapy. Hyperbaric oxygen therapy may be beneficial but is costly and in some cases, surgery may also improve results. These ulcers are responsible for more than 80.0% of all diabetes-related lower-leg amputations and occur in around 15.0% of diabetic patients.

High cost of ulcer management has been restricting the market from realizing its utmost potential. Many developing and underdeveloped countries demonstrate a lack of healthcare facilities, subsequently limiting market growth. However, adoption of novel therapeutics, improved biologics, and continued prioritization to avoid surgeries and amputations are estimated to offset limitations affecting the growth of the market. Thus, in turn, offering significant opportunities for the market to generate revenue.

Treatment Insights

On the basis of treatment, the market has been categorized into wound care dressings, biologics, therapy devices, antibiotic medications, and others. Biologics dominated the market, followed by wound care dressings in 2017. They have been divided into growth factors and skin grafts. Biologics are expected to register the highest CAGR during the forecast period.

Wound care dressings have been further segmented into alginate dressings, hydrofiber dressings, foam dressings, film dressing, hydrocolloid dressings, surgical dressings, and hydrogel dressings. Foam dressings were at the forefront among different types of wound care dressings in 2017.Therapy devices have been bifurcated into negative pressure wound therapy and ultrasound therapy. Spiraling adoption of medical devices for an efficacious, better targeted, and safer treatment of patients is likely to create an upswing in the demand for diabetic foot ulcer therapy devices.

Ulcer Type Insights

The global DFU treatment market has been categorized into neuropathic, ischemic, and neuro-ischemic ulcers. According to various studies in 1980s, neuropathy was the leading cause responsible for diabetic foot ulcers. However, in the last two decades, there has been an increase in the number of cases of neuro-ischemic or ischemic ulceration in the last two decades.

Neuro-ischemic ulcers are the most prevailing among three types, followed by neuropathic and ischemic, respectively. Neuro-ischemic ulcers accounted for the largest share in the market in 2017. Through the forecast period, they are projected to exhibit the fastest growth, followed by neuropathic ulcers.

Regional Insights

North America led the market in 2017. Rising cohort of diabetic patients and adequate healthcare facilities in the region are key factors responsible for the growth of the regional market. Long R&D and approval cycles are required due to capital-intensive naturein North America, which act as a stumbling stone for the growth of the market in the region. However, rising adoption of novel biologics and wound care devices for treatment of these ulcers are contributing to the dominance of North America.

Europe held the second largest share in the market, followed by Asia Pacific. APAC will exhibit the highest CAGR during the forecast period. Increasing prevalence of diabetes and a large geriatric population base in both India and China are supporting the growth of the regional market. This can also be attributed to increased adoption and favorable legislation in developed economies such as Japan and Australia.

Diabetic Foot Ulcer Treatment Market Share Insights

Some of the prominent companies operating in the market are ConvaTec, Inc.; Acelity L.P. Inc.; 3M Healthcare; Coloplast A/S; Smith & Nephew Plc.; B. Braun Melsungen AG; Medline Industries, Inc.; Medtronic Plc.; Organogenesis, Inc.; Molnlycke Health Care AB; and BSN Medical GMBH. The players focus on alliances, strategic planning, new treatment planning, and research activities to achieve favorable growth. Currently, Smith & Nephew, Coloplast, CovanTec, Acelity and 3M Healthcare are leading the market, supported by strong sales of their marketed therapeutic options for the treatment of diabetic foot ulcer.

Potential launches of promising late-stage pipeline products such asFirstString Research’s Granexin gel, ViroMed’s VM 202, and Oneness Biotech’s WH-1 ointment will further drive the market. Few of the other players actively investing in this arena include Centaur Pharmaceuticals Pvt. Ltd.; MediWound Ltd.; Izun Pharmaceuticals Corp.; Issar Pharmaceuticals Pvt. Ltd.; Novalead Pharma Pvt. Ltd.; Karyopharm Therapeutics Inc.; Aurealis Pharma AG; Stratatech Corp.; and ZZ Biotech, LLC.

Report Scope

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis on industry trends in each of the sub segments from 2016 to 2025. For the purpose of this study, Grand View Research has segmented the global diabetic foot ulcer treatment market report on the basis of treatment, ulcer type, and region:

• Treatment Outlook (Revenue, USD Million, 2016 - 2025)

  • Wound Care Dressings

    • Alginate Dressings

    • Hydrofiber Dressings

    • Foam Dressings

    • Film Dressing

    • Hydrocolloid Dressings

    • Surgical Dressings

    • Hydrogel Dressings

  • Biologics

    • Growth Factors

    • Skin Grafts

  • Therapy Devices

    • Negative Pressure Wound Therapy

    • Ultrasound Therapy

  • Antibiotic Medications

  • Others

• Ulcer Type Outlook (Revenue, USD Million; 2016 - 2025)

  • Neuropathic Ulcers

  • Ischemic Ulcers

  • Neuro-ischemic Ulcers

• Regional Outlook (Revenue, USD Million; 2016 - 2025)

  • North America

    • U.S.

    • Canada

  • Europe

    • Germany

    • U.K.

  • Asia Pacific

    • Japan

    • China

    • India

  • Latin America

    • Brazil

    • Mexico

  • MEA

    • South Africa